✦ LIBER ✦

Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule

✍ Scribed by Lynn Feun; Manuel Modiano; King Lee; John Mao; Angela Marini; Niramol Savaraj; Patricia Plezia; Bijan Almassian; Elizabeth Colacino; Jessica Fischer; Susan MacDonald

Publisher: Springer
Year: 2002
Tongue: English
Weight: 121 KB
Volume: 50
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-002-0480-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I and pharmacokinetic study of o

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study

✍ Joseph Chao; Timothy W. Synold; Robert J. Morgan; Charles Kunos; Jeff Longmate; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 259 KB

ChemInform Abstract: Synthesis and Biolo

ChemInform Abstract: Synthesis and Biological Evaluation of a Water Soluble Phosphate Prodrug of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (3-AP).

✍ Jun Li; Xiang Luo; Qin Wang; Li-mou Zheng; I. King; Terrence W. Doyle; Shu-Hui C 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 31 KB 👁 1 views

A Phase I study of the novel ribonucleot

A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

✍ Judith E. Karp; Francis J. Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 117 KB